Congenital nephrotic syndrome

Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Retrieved on: 
Thursday, October 26, 2023

DUBLIN, Oct. 26, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, recently shared findings from Mallinckrodt's latest health economics outcomes research on Acthar® Gel (repository corticotropin injection) for patients with advanced symptomatic sarcoidosis and nephrotic syndrome (NS)1,2 at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 in Orlando, FL October 16-19, 2023.

Key Points: 
  • Patients were monitored at the end of a three-month cycle for a partial or complete response.
  • The full data manuscript from this study was published in ClinicoEconomics and Outcomes Research on October 17, 2023.
  • "We are pleased to have shared our latest health economics research on Acthar Gel.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economics outcomes may not be solely attributable to Acthar.

Global Nephrotic Syndrome Diagnostics & Therapeutics Market 2022: Featuring Abbott, AstraZeneca, Eli Lilly, GlaxoSmithKline & More - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022

The "Global Nephrotic Syndrome Diagnostics & Therapeutics Market Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nephrotic Syndrome Diagnostics & Therapeutics Market Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global nephrotic syndrome diagnostics & therapeutics market is anticipated to grow at a CAGR of 5.6% during the forecast period.
  • Nephrotic syndrome is a kidney disease in which the body excretes an excessive amount of protein in the urine.
  • Moreover, pipeline drugs for nephrotic syndrome would drive the demand creating opportunities for the growth of the market.

Calliditas announces poster presentations at ASN Digital Kidney Week 2021

Retrieved on: 
Wednesday, November 3, 2021

STOCKHOLM, Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology (ASN) annual Kidney Week 2021 conference, which will be held virtually November 2-7, 2021.

Key Points: 
  • STOCKHOLM, Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology (ASN) annual Kidney Week 2021 conference, which will be held virtually November 2-7, 2021.
  • In addition, Laura Prez-Als will present a poster titled "Treatment with Targeted Release Formulation Budesonide (Nefecon) Modulates the Complement System in Patients with IgA Nephropathy".
  • "We are delighted that these posters have been selected for the upcoming ASN Digital Kidney Week 2021 and congratulate the authors.
  • Calliditas is also planning to start clinical trials with NOX inhibitors in primary biliary cholangitis and head and neck cancer.

Calliditas announces poster presentations at ASN Digital Kidney Week 2021

Retrieved on: 
Wednesday, November 3, 2021

STOCKHOLM, Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology (ASN) annual Kidney Week 2021 conference, which will be held virtually November 2-7, 2021.

Key Points: 
  • STOCKHOLM, Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology (ASN) annual Kidney Week 2021 conference, which will be held virtually November 2-7, 2021.
  • In addition, Laura Prez-Als will present a poster titled "Treatment with Targeted Release Formulation Budesonide (Nefecon) Modulates the Complement System in Patients with IgA Nephropathy".
  • "We are delighted that these posters have been selected for the upcoming ASN Digital Kidney Week 2021 and congratulate the authors.
  • Calliditas is also planning to start clinical trials with NOX inhibitors in primary biliary cholangitis and head and neck cancer.

ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome

Retrieved on: 
Tuesday, August 31, 2021

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq:ANIP) today announced that the Companys supplemental New Drug Application (sNDA) for Purified Cortrophin Gel (Cortrophin Gel) has been accepted by the U.S. Food and Drug Administration (FDA) for review.

Key Points: 
  • ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq:ANIP) today announced that the Companys supplemental New Drug Application (sNDA) for Purified Cortrophin Gel (Cortrophin Gel) has been accepted by the U.S. Food and Drug Administration (FDA) for review.
  • FDAs acceptance of our sNDA for Cortrophin Gel marks a significant milestone for ANI.
  • We look forward to further productive engagement with the FDA, and in parallel, we are focused on preparations for the launch of Cortrophin Gel, stated Nikhil Lalwani, Chief Executive Officer of ANI Pharmaceuticals.
  • Purified Cortrophin Gel (Repository Corticotropin Injection USP) is a purified adrenocorticotropic hormone (ACTH) previously approved in the U.S. for multiple indications including multiple sclerosis (MS), rheumatoid arthritis (RA), and nephrotic syndrome (NS).